Clinical Trial Update: BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial update for BI 425809 in cognitive impairment due to Alzheimer’s disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BI 425809 (BI-425809)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-11-06